Products are not intended to be used as drugs, medical devices, or diagnostic tools, and are not classified as such
Avoid typical billing problems by following payer-specific regulations
While BPC-157, TB-500, KPV, and GHK-Cu injections have not been studied for safety and efficacy in large-scale human clinical trials, some risks may be hypothesized from their mechanisms of action
The most commonly reported effects include: Mild water retention during the first 2 to 4 weeks Occasional headaches, particularly at treatment initiation Redness or irritation at the injection site Tingling or numbness in the extremities Short term fatigue or flushing after injection Ipamorelins selectivity provides a meaningful safety advantage
Can my employer test specifically for peptides if they suspect use
How long does an IV of B12 last